Sandoz Archives - Green Market Report

Debra BorchardtDecember 18, 2018
ClosingBell-tilray-Nasdaq-1280x854.jpg

3min00

Tilray Canada Ltd., a subsidiary of Tilray Inc. (NASDAQ: TLRY) entered into an agreement with Sandoz AG, which is a part of the Novartis group, to increase the availability of high-quality medical cannabis products across the world.

According to the company statement, the Tilray and Sandoz agreement would be as follows:

  • Sandoz AG may support the global commercialization of Tilray’s non-smokable/non-combustible medical cannabis products;
  • Tilray and Sandoz AG may co-brand certain non-smokable/non-combustible products;
  • Tilray may supply non-smokable/ non-combustible medical cannabis products and license rights to and from Sandoz AG in relation to such products; Both companies may also partner to leverage best-in-class knowledge to educate pharmacists and physicians about medical cannabis products;
  • Tilray and Sandoz AG may collaborate to develop new innovative medical cannabis products.

“This agreement represents a major milestone in the movement to provide access to safe, GMP-certified medical cannabis to patients in need across the world,” says Brendan Kennedy, Tilray Chief Executive Officer. “Tilray is a global company and we’re thrilled to build upon the success and momentum from our existing agreement with Sandoz Canada by taking our partnership global. Sandoz AG will be a valuable partner as we work together to improve access to the highest quality medical cannabis products in countries all over the world.”

Tilray already has products available in twelve countries and operations in Australia & New Zealand, Canada, Germany, Latin America, and Portugal. This agreement builds on Tilray’s pioneering track-record as a company committed to making pharmaceutical-grade medical cannabis products available to patients in-need. Tilray was the first licensed medical cannabis producer in North America to obtain current Good Manufacturing Practice certification in accordance with the European Medicines Agency’s standards.

Tilray stock jumped over 9% in pre-market trading to lately trade at $72.25. This is still way below the frenzy price of $300, but well above the company’s 52-week low of $20.


Debra BorchardtMarch 19, 2018
brody-tilray-pack1-1280x675.jpg

3min00

Canadian medical marijuana company Tilray has signed a binding letter of intent (LOI) to collaborate with generic pharmaceutical company Sandoz Canada Inc., an affiliate of Sandoz International GmbH, which is part of the Novartis Group (NVS).  The two companies are working together in order to accelerate innovation and increase the availability of high-quality cannabis products.

“This agreement is a major milestone on the long road to legitimizing medical cannabis as conventional medicine,” said Brendan Kennedy, Chief Executive Officer of Tilray. “Tilray is pleased to be what we believe is, the first federally licensed producer of medical cannabis to form a strategic alliance with a local affiliate of a global pharmaceutical company to improve the availability and quality of medical cannabis products for Canadian patients in need.”

The agreement builds on Tilray’s track record as a company that makes pharmaceutical grade medical cannabis. It was the first medical cannabis company to obtain current Good Manufacturing Practice (cGMP) certification in accordance with the EMA. The company supplies thousands of patients in ten countries.

With this collaboration, Tilray will be able to leverage the Sandoz salesforce to better educate pharmacists and physicians about medical marijuana. It will become the exclusive partner of Sandoz with respect to non-smokable/non-combustible medical marijuana products. The two companies will also develop new medical cannabis products that aren’t smokable.

They hope that in the future, if there are regulatory changes, Tilray will be able to capitalize on Sandoz’s supply chain with Canadian hospitals and pharmacies.

Tilray is a private company owned by Privateer Holdings.  Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. The Sandoz segment of the company provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services.

 


Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.